161 related articles for article (PubMed ID: 36450385)
1. Phase II clinical and immune correlate study of adjuvant nivolumab plus ipilimumab for high-risk resected melanoma.
Khushalani NI; Vassallo M; Goldberg JD; Eroglu Z; Kim Y; Cao B; Ferguson R; Monson KR; Kirchhoff T; Amato CM; Burke P; Strange A; Monk E; Gibney GT; Kudchadkar R; Markowitz J; Brohl AS; Pavlick A; Richards A; Woods DM; Weber J
J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 36450385
[TBL] [Abstract][Full Text] [Related]
2. Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial.
Motzer RJ; Escudier B; McDermott DF; Arén Frontera O; Melichar B; Powles T; Donskov F; Plimack ER; Barthélémy P; Hammers HJ; George S; Grünwald V; Porta C; Neiman V; Ravaud A; Choueiri TK; Rini BI; Salman P; Kollmannsberger CK; Tykodi SS; Grimm MO; Gurney H; Leibowitz-Amit R; Geertsen PF; Amin A; Tomita Y; McHenry MB; Saggi SS; Tannir NM
J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32661118
[TBL] [Abstract][Full Text] [Related]
3. Long-term outcomes with nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma.
Rini BI; Signoretti S; Choueiri TK; McDermott DF; Motzer RJ; George S; Powles T; Donskov F; Tykodi SS; Pal SK; Gupta S; Lee CW; Jiang R; Tannir NM
J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36549781
[TBL] [Abstract][Full Text] [Related]
4. Ipilimumab and nivolumab combined with anthracycline-based chemotherapy in metastatic hormone receptor-positive breast cancer: a randomized phase 2b trial.
Andresen NK; Røssevold AH; Quaghebeur C; Gilje B; Boge B; Gombos A; Falk RS; Mathiesen RR; Julsrud L; Garred Ø; Russnes HG; Lereim RR; Chauhan SK; Lingjærde OC; Dunn C; Naume B; Kyte JA
J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38242720
[TBL] [Abstract][Full Text] [Related]
5. Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab.
Chapman PB; Jayaprakasam VS; Panageas KS; Callahan M; Postow MA; Shoushtari AN; Wolchok JD; Betof Warner A
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34702752
[TBL] [Abstract][Full Text] [Related]
6. Nivolumab with or without ipilimumab in pediatric patients with high-grade CNS malignancies: Safety, efficacy, biomarker, and pharmacokinetics-CheckMate 908.
Dunkel IJ; Doz F; Foreman NK; Hargrave D; Lassaletta A; André N; Hansford JR; Hassall T; Eyrich M; Gururangan S; Bartels U; Gajjar A; Howell L; Warad D; Pacius M; Tam R; Wang Y; Zhu L; Cohen K
Neuro Oncol; 2023 Aug; 25(8):1530-1545. PubMed ID: 36808285
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238.
Larkin J; Del Vecchio M; Mandalá M; Gogas H; Arance Fernandez AM; Dalle S; Cowey CL; Schenker M; Grob JJ; Chiarion-Sileni V; Marquez-Rodas I; Butler MO; Di Giacomo AM; Middleton MR; Lutzky J; de la Cruz-Merino L; Arenberger P; Atkinson V; Hill AG; Fecher LA; Millward M; Nathan PD; Khushalani NI; Queirolo P; Ritchings C; Lobo M; Askelson M; Tang H; Dolfi S; Ascierto PA; Weber J
Clin Cancer Res; 2023 Sep; 29(17):3352-3361. PubMed ID: 37058595
[TBL] [Abstract][Full Text] [Related]
8. Nivolumab Plus Ipilimumab in Patients With Advanced Melanoma: Updated Survival, Response, and Safety Data in a Phase I Dose-Escalation Study.
Callahan MK; Kluger H; Postow MA; Segal NH; Lesokhin A; Atkins MB; Kirkwood JM; Krishnan S; Bhore R; Horak C; Wolchok JD; Sznol M
J Clin Oncol; 2018 Feb; 36(4):391-398. PubMed ID: 29040030
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915).
Weber JS; Schadendorf D; Del Vecchio M; Larkin J; Atkinson V; Schenker M; Pigozzo J; Gogas H; Dalle S; Meyer N; Ascierto PA; Sandhu S; Eigentler T; Gutzmer R; Hassel JC; Robert C; Carlino MS; Di Giacomo AM; Butler MO; Muñoz-Couselo E; Brown MP; Rutkowski P; Haydon A; Grob JJ; Schachter J; Queirolo P; de la Cruz-Merino L; van der Westhuizen A; Menzies AM; Re S; Bas T; de Pril V; Braverman J; Tenney DJ; Tang H; Long GV
J Clin Oncol; 2023 Jan; 41(3):517-527. PubMed ID: 36162037
[TBL] [Abstract][Full Text] [Related]
10. Adaptive Dosing of Nivolumab + Ipilimumab Immunotherapy Based Upon Early, Interim Radiographic Assessment in Advanced Melanoma (The ADAPT-IT Study).
Postow MA; Goldman DA; Shoushtari AN; Betof Warner A; Callahan MK; Momtaz P; Smithy JW; Naito E; Cugliari MK; Raber V; Eton O; Nair SG; Panageas KS; Wolchok JD; Chapman PB
J Clin Oncol; 2022 Apr; 40(10):1059-1067. PubMed ID: 34928709
[TBL] [Abstract][Full Text] [Related]
11. A matching-adjusted indirect comparison of combination nivolumab plus ipilimumab with BRAF plus MEK inhibitors for the treatment of BRAF-mutant advanced melanoma
Tarhini AA; Toor K; Chan K; McDermott DF; Mohr P; Larkin J; Hodi FS; Lee CH; Rizzo JI; Johnson H; Moshyk A; Rao S; Kotapati S; Atkins MB
ESMO Open; 2021 Apr; 6(2):100050. PubMed ID: 33556898
[TBL] [Abstract][Full Text] [Related]
12. Nivolumab Plus Ipilimumab for Treatment-Naïve Metastatic Uveal Melanoma: An Open-Label, Multicenter, Phase II Trial by the Spanish Multidisciplinary Melanoma Group (GEM-1402).
Piulats JM; Espinosa E; de la Cruz Merino L; Varela M; Alonso Carrión L; Martín-Algarra S; López Castro R; Curiel T; Rodríguez-Abreu D; Redrado M; Gomà M; Rullán AJ; Calvo González A; Berrocal-Jaime A
J Clin Oncol; 2021 Feb; 39(6):586-598. PubMed ID: 33417511
[TBL] [Abstract][Full Text] [Related]
13. Nivolumab and ipilimumab are associated with distinct immune landscape changes and response-associated immunophenotypes.
Woods DM; Laino AS; Winters A; Alexandre J; Freeman D; Rao V; Adavani SS; Weber JS; Chattopadhyay PK
JCI Insight; 2020 Jun; 5(11):. PubMed ID: 32369447
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of first-line nivolumab plus ipilimumab alternating with nivolumab monotherapy in patients with advanced renal cell carcinoma: the non-randomised, open-label, phase IIIb/IV CheckMate 920 trial.
George DJ; Spigel DR; Gordan LN; Kochuparambil ST; Molina AM; Yorio J; Rezazadeh Kalebasty A; McKean H; Tchekmedyian N; Tykodi SS; Zhang J; Askelson M; Johansen JL; Hutson TE
BMJ Open; 2022 Sep; 12(9):e058396. PubMed ID: 36104138
[TBL] [Abstract][Full Text] [Related]
15. Nivolumab plus ipilimumab versus sunitinib in previously untreated advanced renal-cell carcinoma: analysis of Japanese patients in CheckMate 214 with extended follow-up.
Tomita Y; Kondo T; Kimura G; Inoue T; Wakumoto Y; Yao M; Sugiyama T; Oya M; Fujii Y; Obara W; Motzer RJ; Uemura H
Jpn J Clin Oncol; 2020 Jan; 50(1):12-19. PubMed ID: 31633185
[TBL] [Abstract][Full Text] [Related]
16. Ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma: a multicenter study of the prospective skin cancer registry ADOREG.
Glutsch V; Schummer P; Kneitz H; Gesierich A; Goebeler M; Klein D; Posch C; Gebhardt C; Haferkamp S; Zimmer L; Becker JC; Leiter U; Weichenthal M; Schadendorf D; Ugurel S; Schilling B
J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 36450381
[TBL] [Abstract][Full Text] [Related]
17. Prospective Single-Arm Phase 1 and 2 Study: Ipilimumab and Nivolumab With Thoracic Radiation Therapy After Platinum Chemotherapy in Extensive-Stage Small Cell Lung Cancer.
Perez BA; Kim S; Wang M; Karimi AM; Powell C; Li J; Dilling TJ; Chiappori A; Latifi K; Rose T; Lannon A; MacMillan G; Saller J; Grass GD; Rosenberg S; Gray J; Haura E; Creelan B; Tanvetyanon T; Saltos A; Shafique M; Boyle TA; Schell MJ; Conejo-Garcia JR; Antonia SJ
Int J Radiat Oncol Biol Phys; 2021 Feb; 109(2):425-435. PubMed ID: 33002543
[TBL] [Abstract][Full Text] [Related]
18. Safety of First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC: A Pooled Analysis of CheckMate 227, CheckMate 568, and CheckMate 817.
Paz-Ares LG; Ciuleanu TE; Pluzanski A; Lee JS; Gainor JF; Otterson GA; Audigier-Valette C; Ready N; Schenker M; Linardou H; Caro RB; Provencio M; Zurawski B; Lee KH; Kim SW; Caserta C; Ramalingam SS; Spigel DR; Brahmer JR; Reck M; O'Byrne KJ; Girard N; Popat S; Peters S; Memaj A; Nathan F; Aanur N; Borghaei H
J Thorac Oncol; 2023 Jan; 18(1):79-92. PubMed ID: 36049658
[TBL] [Abstract][Full Text] [Related]
19. Hospitalization and emergency department utilization in patients with advanced melanoma receiving pembrolizumab versus ipilimumab plus nivolumab in US academic centers.
Joseph RW; Shillington AC; Lee TA; Macahilig CP; Diede SJ; Dave V; Harshaw Q; Scherrer E; Liu FX
J Med Econ; 2020 Feb; 23(2):132-138. PubMed ID: 31750751
[No Abstract] [Full Text] [Related]
20. Combining Melphalan Percutaneous Hepatic Perfusion with Ipilimumab Plus Nivolumab in Advanced Uveal Melanoma: First Safety and Efficacy Data from the Phase Ib Part of the Chopin Trial.
Tong TML; Burgmans MC; Speetjens FM; van Erkel AR; van der Meer RW; van Rijswijk CSP; Jonker-Bos MA; Roozen CFM; Sporrel-Blokland M; Lutjeboer J; van Persijn van Meerten EL; Martini CH; Zoethout RWM; Tijl FGJ; Blank CU; Kapiteijn E
Cardiovasc Intervent Radiol; 2023 Mar; 46(3):350-359. PubMed ID: 36624292
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
